About ADMA Biologics
ADMA Biologics is a company based in Ramsey (United States) founded in 2005 by Adam Grossman.. ADMA Biologics has raised $17.55 million across 6 funding rounds from investors including Hercules Capital, Oxford Finance and Perceptive Advisors. The company has 685 employees as of December 31, 2024. ADMA Biologics offers products and services including ASCENIV, BIVIGAM, and Nabi-HB. ADMA Biologics operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
- Headquarter Ramsey, United States
- Employees 685 as on 31 Dec, 2024
- Founders Adam Grossman
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Adma Biologics Inc
-
Annual Revenue
$426.45 M65.15as on Dec 31, 2024
-
Net Profit
$197.67 M0as on Dec 31, 2024
-
EBITDA
$147.03 M390.68as on Dec 31, 2024
-
Total Equity Funding
$17.55 M (USD)
in 6 rounds
-
Latest Funding Round
$72.5 M (USD), Debt – Conventional
Feb 12, 2019
-
Investors
Hercules Capital
& 4 more
-
Employee Count
685
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ADMA Biologics
ADMA Biologics is a publicly listed company on the NASDAQ with ticker symbol ADMA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of ADMA Biologics
ADMA Biologics offers a comprehensive portfolio of products and services, including ASCENIV, BIVIGAM, and Nabi-HB. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for primary immunodeficiency diseases.
Immune globulin product for medical applications.
Hepatitis B immune globulin for infection prevention.
Unlock access to complete
Unlock access to complete
Funding Insights of ADMA Biologics
ADMA Biologics has successfully raised a total of $17.55M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $72.5 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Debt – Conventional — $72.5M
-
First Round
First Round
(28 Feb 2012)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2019 | Amount | Debt – Conventional - ADMA Biologics | Valuation |
investors |
|
| Jun, 2015 | Amount | Debt – Venture - ADMA Biologics | Valuation |
investors |
|
| Dec, 2014 | Amount | Debt – Venture - ADMA Biologics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ADMA Biologics
ADMA Biologics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, Oxford Finance and Perceptive Advisors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Venture debt firm focused on the life sciences sector
|
Founded Year | Domain | Location | |
|
Venture debt financing is provided to companies in multiple sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ADMA Biologics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ADMA Biologics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Adma Biologics Comparisons
Competitors of ADMA Biologics
ADMA Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Adma Biologics
Frequently Asked Questions about ADMA Biologics
When was ADMA Biologics founded?
ADMA Biologics was founded in 2005 and raised its 1st funding round 7 years after it was founded.
Where is ADMA Biologics located?
ADMA Biologics is headquartered in Ramsey, United States. It is registered at Ramsey, Minnesota, United States.
Who is the current CEO of ADMA Biologics?
Adam Grossman is the current CEO of ADMA Biologics. They have also founded this company.
Is ADMA Biologics a funded company?
ADMA Biologics is a funded company, having raised a total of $17.55M across 6 funding rounds to date. The company's 1st funding round was a Debt – Venture of $5M, raised on Feb 28, 2012.
How many employees does ADMA Biologics have?
As of Dec 31, 2024, the latest employee count at ADMA Biologics is 685.
What is the annual revenue of ADMA Biologics?
Annual revenue of ADMA Biologics is $426.45M as on Dec 31, 2024.
What does ADMA Biologics do?
ADMA Biologics was founded in 2005 and is headquartered in Ramsey, United States. Operations focus on the development, manufacturing, and marketing of plasma-derived immune globulins targeted at niche patient populations. These biologics address primary immune deficiency diseases and certain infectious conditions. The lead product, RI-002, completed phase 3 clinical trials, with a biologics license application submitted to the FDA in 2015.
Who are the top competitors of ADMA Biologics?
ADMA Biologics's top competitors include BioNTech, Generate Biomedicines and Kymeratx.
What products or services does ADMA Biologics offer?
ADMA Biologics offers ASCENIV, BIVIGAM, and Nabi-HB.
Is ADMA Biologics publicly traded?
Yes, ADMA Biologics is publicly traded on NASDAQ under the ticker symbol ADMA.
Who are ADMA Biologics's investors?
ADMA Biologics has 5 investors. Key investors include Hercules Capital, Oxford Finance, Perceptive Advisors, Burrill and Company, and Aisling Capital.
What is ADMA Biologics's ticker symbol?
The ticker symbol of ADMA Biologics is ADMA on NASDAQ.